Approval Of Additional Indication Of NESINA®: Combination Therapy With Thiazolidinediones For Type 2 Diabetes In Japan
Links shared publicly online about this topic.
- 932total visits
Approval Of Additional Indication Of NESINA®: Combination Therapy With Thiazolidinediones For Type 2 Diabetes In Japan
View full resource at medicalnewstoday.com
Tags: Diabetes, Type 2 Diabetes, Pharma
Most Recently Shared on August 21, 2010 at 4:00 pm By:
Approval Of Additional Indication Of NESINA®: Combination Therapy With Thiazolidinediones For Type 2 Diabetes In J... http://mnt.to/3HHx
Also Shared By:
Istodax Gains Indication for T-cell Lymphoma - ONA
oncologynurseadvisor.com — “Celgene Corporation announced that the FDA has granted accelerated approval for its supplemental New Drug Application (sNDA) for an additional indication for Istodax (romidepsin injection): the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 17, 2011 at 3:01 pm By:
OncologyNurseAdvisor Medical Publisher, Oncology, Nursing, and Medical Education
Istodax Gains Indication for T-cell Lymphoma http://goo.gl/fb/qyU3q
Istodax Gains Indication for T-cell Lymphoma - MPR
empr.com — “Celgene Corporation announced that the FDA has granted accelerated approval for its supplemental New Drug Application (sNDA) for an additional indication for Istodax (romidepsin injection): the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.” View full resource at empr.com
Most Recently Shared on June 17, 2011 at 2:49 pm By:
MPR News: Istodax Gains Indication for T-cell Lymphoma: Celgene Corporation announced that the FDA has granted a... http://bit.ly/mJSezc
Licence changes and product updates news | MIMS online
mims.co.uk — “Medical drug news from MIMS online.” View full resource at mims.co.uk
Most Recently Shared on April 4, 2011 at 8:57 am By:
Episenta (valproate), Invega (paliperidone) and Cozaar (losartan) have been approved for additional indications: http://bit.ly/gR8IXo
Accelerated approval for oncology drugs successful, but improvements needed | HemOncToday
hemonctoday.com — “In the past 18 years, 47 new indications for 35 oncology drugs received accelerated approval from the FDA. In addition, post-approval trials” View full resource at hemonctoday.com
Most Recently Shared on March 28, 2011 at 1:38 pm By:
HemOnc Today Oncology and Health News
Accelerated approval for oncology drugs successful, but improvements needed http://bit.ly/dRJmah
National Kidney Cancer Awareness Month - Avastin (bevacizumab)
avastin.com — “Learn about tumor-starving therapy and its use in treating mRCC. Indication: Avastin, in combination with interferon alfa, is approved by the FDA for the treatment of metastatic kidney cancer. Possible Serious Side Effects and Additional Important Safety Information What is the most important safety information I should know about Avastin? Avastin can result in the development of a potentially serious, and sometimes fatal, side effect called gastrointestinal (GI) perforation. GI perforation is t” View full resource at avastin.com
Most Recently Shared on March 7, 2011 at 5:25 pm By:
March is National Kidney Month. 50K diagnosed w/ kidney cancer in '10. Learn more, get involved at http://bit.ly/emzSms
National Colorectal Cancer Awareness Month - Avastin (bevacizumab)
avastin.com — “Avastin (bevacizumab) has been approved by the FDA in combination with a specific type of chemotherapy (intravenous 5-fluorouracil [5FU]-based chemotherapy) for treatment of people diagnosed with metastatic colorectal cancer for the first time. Indication: Avastin, in combination with intravenous 5-FU–based chemotherapy, is approved by the FDA for first- or second-line treatment of people with metastatic cancer of the colon or rectum. Possible Serious Side Effects and Additional Important ” View full resource at avastin.com
Most Recently Shared on March 2, 2011 at 4:55 pm By:
March = Colorectal Cancer Awareness Month. 143K Americans diagnosed in ‘10. Visit http://bit.ly/hTpej8 for more info
Furiex Pharmaceuticals / Furiex Confirms Takeda Receives Approval of Additional NESINA® Combination Therapies with Sulfonylurea and Biguanide for Type 2 Diabetes in Japan
investor.furiex.com — “Furiex Pharmaceuticals / Furiex Confirms Takeda Receives Approval of Additional NESINA® Combination Therapies with Sulfonylurea and Biguanide for Type 2 Diabetes in Japan” View full resource at investor.furiex.com
Most Recently Shared on February 28, 2011 at 5:58 pm By:
Symposier Endocrino Health Site
Furiex Confirms Takeda Receives Approval of Additional NESINA® Combination Therapies for Type 2 Diabetes in Japan. http://bit.ly/fAoxP7
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide For Type 2 Diabetes In Japan
medicalnewstoday.com — “Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) confirmed that Takeda Pharmaceutical Company Limited's applications for two additional indications for NESINA® (alogliptin), combination therapy w” View full resource at medicalnewstoday.com
Most Recently Shared on February 28, 2011 at 5:05 pm By:
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide... http://mnt.to/3RGd
Saphris gains indications - ONA
oncologynurseadvisor.com — “Merck announced that Saphris (asenapine sublingual tablets) has been approved for two additional indications: 1) the maintenance treatment of schizophrenia and 2) as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.” View full resource at oncologynurseadvisor.com
Most Recently Shared on January 25, 2011 at 7:47 pm By:
OncologyNurseAdvisor Medical Publisher, Oncology, Nursing, and Medical Education
Saphris gains indications http://goo.gl/fb/fG2TE
Saphris gains indications - MPR
empr.com — “Merck announced that Saphris (asenapine sublingual tablets) has been approved for two additional indications: 1) the maintenance treatment of schizophrenia and 2) as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.” View full resource at empr.com
Most Recently Shared on January 25, 2011 at 7:25 pm By:
MPR News: Saphris gains indications: Merck announced that Saphris (asenapine sublingual tablets) has been approv... http://bit.ly/i8jUas
Therapeutics Daily
therapeuticsdaily.com — “Therapeutics Daily” View full resource at therapeuticsdaily.com
Most Recently Shared on November 1, 2010 at 6:13 pm By:
PharmaLive Pharma and Health News
Therapeutics Daily - FDA Approves Additional Medical Indication for Sprycel - http://tinyurl.com/279xfw4
FDA Approves Additional Medical Indication for Sprycel - Drugs.com MedNews
drugs.com — “Patients with rare type of leukemia now have another treatment option The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatin” View full resource at drugs.com
Most Recently Shared on October 29, 2010 at 1:16 pm By:
Drugs and Devices OW OW Health
FDA Approves Additional Medical Indication for Sprycel: Patients with rare type of leukemia now have another ... http://bit.ly/c4kBZd #drug
FDA approves additional medical indication for Sprycel
drugs.com — “Sprycel (dasatinib) is now approved to treat newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. Includes Sprycel side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 28, 2010 at 11:24 pm By:
Drugs and Devices OW OW Health
FDA approves additional medical indication for Sprycel: SILVER SPRING, Md., Oct. 28 - The U.S. Food and Drug ... http://bit.ly/cA1b5e #drug
FDA approves additional medical indication for Sprycel
drugs.com — “Sprycel (dasatinib) is now approved to treat newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. Includes Sprycel side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 28, 2010 at 10:35 pm By:
FDA approves additional medical indication for Sprycel - http://bit.ly/cudetK
Medical News: Dasatinib Wins First-Line Indication in CML - in Oncology/Hematology, Leukemia from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA approved an additional indication for dasatinib (Sprycel) as a first-line therapy for patients with Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ C” View full resource at medpagetoday.com
Most Recently Shared on October 28, 2010 at 9:29 pm By:
Dasatinib Wins First-Line Indication in CML http://ow.ly/19GFT4
Advertisement
MNT Diabetes News
@mnt_diabetes
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide... http://mnt.to/3RGd
1 year ago...